Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study.

What Was Tested

This randomized controlled trial looks at Magnesium Hydroxide.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

A 2-week, medication free, washout period was required before receiving treatment, between blinded courses, and again before starting open label treatment.

How the Study Was Run

The design is described as randomized, double-blind, open-label, placebo-controlled, crossover and pilot.

The participants were allocated by chance, so the Magnesium Hydroxide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Magnesium Hydroxide, so expectations could not easily colour the readings.

Everyone knew when Magnesium Hydroxide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A placebo (an inactive look-alike) gave the Magnesium Hydroxide group a baseline to be compared against.

The 3 primary outcome variables were measures of pain and tenderness but functional and psychological measures were also assessed.

What Was Measured

Topics PubMed links to this paper include Drug Combinations, Fibromyalgia, Magnesium Hydroxide, Malates and Pilot Projects.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Magnesium Hydroxide.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1995 (The Journal of rheumatology), a journal based in Canada.

More context: all human trials.